12,107 Intuitive Surgical, Inc. $ISRG Shares Sold by Aberdeen Group plc

Aberdeen Group plc lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 411,217 shares of the medical equipment provider’s stock after selling 12,107 shares during the period. Aberdeen Group plc’s holdings in Intuitive Surgical were worth $167,213,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. ProVise Management Group LLC raised its position in Intuitive Surgical by 36.8% during the 3rd quarter. ProVise Management Group LLC now owns 1,096 shares of the medical equipment provider’s stock worth $446,000 after buying an additional 295 shares during the last quarter. EagleClaw Capital Managment LLC lifted its stake in Intuitive Surgical by 51.2% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 18,527 shares of the medical equipment provider’s stock valued at $7,534,000 after acquiring an additional 6,277 shares during the period. Moors & Cabot Inc. lifted its stake in Intuitive Surgical by 14.2% during the 3rd quarter. Moors & Cabot Inc. now owns 2,702 shares of the medical equipment provider’s stock valued at $1,099,000 after acquiring an additional 335 shares during the period. Compass Capital Management Inc. boosted its holdings in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Compass Capital Management Inc. now owns 19,803 shares of the medical equipment provider’s stock valued at $8,052,000 after acquiring an additional 282 shares during the last quarter. Finally, Money Concepts Capital Corp lifted its position in Intuitive Surgical by 13.8% during the third quarter. Money Concepts Capital Corp now owns 3,514 shares of the medical equipment provider’s stock valued at $1,429,000 after purchasing an additional 425 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on ISRG shares. Royal Bank Of Canada lowered their price target on shares of Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating on the stock in a report on Wednesday, October 21st. TD Cowen reiterated a “buy” rating and set a $485.00 price objective on shares of Intuitive Surgical in a research note on Monday, October 19th. BTIG Research reissued a “buy” rating and issued a $454.00 price objective on shares of Intuitive Surgical in a report on Wednesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Intuitive Surgical in a report on Thursday. Finally, Robert W. Baird lifted their price target on Intuitive Surgical from $513.00 to $550.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.54.

Intuitive Surgical Trading Up 0.8%

ISRG opened at $443.59 on Friday. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The firm’s 50-day moving average price is $417.59 and its 200 day moving average price is $429.98. The firm has a market capitalization of $153.77 billion, a PE ratio of 53.64, a PEG ratio of 3.03 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company had revenue of $3.05 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the previous year, the firm earned $2.40 earnings per share. Intuitive Surgical’s quarterly revenue was up 21.7% compared to the same quarter last year. As a group, analysts predict that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other news, Director Craig Barratt sold 1,150 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $460.00, for a total value of $529,000.00. Following the completion of the transaction, the director owned 1,150 shares in the company, valued at approximately $529,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $457.34, for a total value of $4,573,400.00. Following the transaction, the director directly owned 1,194,530 shares in the company, valued at approximately $546,306,350.20. The trade was a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,456 shares of company stock worth $17,769,124 over the last three months. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.